GLP1R and type 2 diabetes mellitus: Recent studies in type 2 diabetes also reported regression of coronary non-calcified plaque volume following Sodium-Glucose Transport Protein 2 inhibitor (SGLT2i) therapy and improved coronary plaque stabilization following treatment with both SGLT2i and glucagon-like peptide-1 receptor agonists (GLP1-RA) [38–40].